Table 2.
Baseline Characteristics for ACS and Stable CAD Groups, by Colchicine Administration
| ACS (n=40) | Stable CAD (n=33) | |||||
|---|---|---|---|---|---|---|
| Colchicine | No Colchicine | P Value* | Colchicine | No Colchicine | P Value† | |
| Number | 21 | 19 | — | 13 | 20 | — |
| Age, y—mean (SD) | 65.0 (8.9) | 64.0 (11.7) | 0.76 | 59.9 (11.3) | 61.8 (10.0) | 0.63 |
| Female (%) | 3 (14) | 0 (0) | 0.23 | 1 (8) | 2 (10) | 1 |
| Diabetes mellitus (%) | 10 (48) | 3 (16) | 0.04 | 8 (62) | 5 (25) | 0.06 |
| Hypertension (%) | 13 (62) | 14 (74) | 0.51 | 8 (62) | 11 (55) | 0.71 |
| Dyslipidemia (%) | 13 (62) | 14 (74) | 0.51 | 11 (85) | 12 (60) | 1 |
| Current smoker (%) | 6 (29) | 4 (21) | 0.72 | 1 (8) | 5 (25) | 0.63 |
| Previous MI (%) | 2 (10) | 5 (26) | 0.23 | 6 (46) | 4 (20) | 0.23 |
| Previous PCI (%) | 3 (14) | 4 (21) | 0.69 | 1 (8) | 8 (40) | 0.19 |
| Previous CABG (%) | 0 (0) | 1 (5) | 0.48 | 2 (15) | 4 (20) | 1 |
| Medications | ||||||
| Aspirin (%) | 21 (100) | 19 (100) | — | 13 (100) | 20 (100) | — |
| Thienopyridines (%) | 20 (95) | 18 (95) | 1 | 11 (85) | 15 (75) | 1 |
| β-Blockers (%) | 16 (76) | 14 (74) | 1 | 7 (54) | 10 (50) | 1 |
| ACE-I/ARA-2 (%) | 11 (52) | 14 (74) | 0.20 | 9 (69) | 11 (55) | 0.44 |
| Statins (%) | 19 (91) | 17 (89) | 1 | 11 (85) | 16 (80) | 1 |
| Hypoglycemics (%) | 10 (48) | 2 (11) | 0.02 | 7 (54) | 5 (25) | 0.24 |
| Insulin (%) | 1 (5) | 2 (11) | 0.59 | 1 (8) | 1 (5) | 1 |
ACE-I indicates angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARA-2, angiotensin 2 receptor antagonist; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.
*
Difference between colchicine vs. no colchicine within ACS group.
†
Difference between colchicine vs. no colchicine within stable CAD group.